DiaMedica Therapeutics Inc. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
DiaMedica Therapeutics Inc. (DMAC) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $8.29 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-03-30
- DiaMedica Therapeutics Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2025 was $8.29M, a 35.19% increase from fiscal 2024.
- DiaMedica Therapeutics Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2024 was $6.13M, a 15.70% increase from fiscal 2023.
- DiaMedica Therapeutics Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2023 was $5.30M, a 58.52% increase from fiscal 2022.
- DiaMedica Therapeutics Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2022 was $3.34M, a 6.97% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $8.29M 10-K · filed 2026-03-30 | |
| 2024-12-31 | $6.13M 10-K · filed 2026-03-30 | $6.14M 10-K · filed 2025-03-17 |
| 2023-12-31 | $5.30M 10-K · filed 2025-03-17 | |
| 2022-12-31 | $3.34M 10-K · filed 2024-03-19 | |
| 2021-12-31 | $3.13M 10-K · filed 2023-03-28 | |
| 2020-12-31 | $3.53M 10-K · filed 2022-03-14 | |
| 2019-12-31 | $2.43M 10-K · filed 2021-03-10 | |
| 2018-12-31 | $1.13M 10-K · filed 2020-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |